Opioid genetics in the context of opioid switching

Current Opinion in Supportive and Palliative Care

Volumn 6, Issue 1, 2012, Pages 10-16

  Droney, Joanne ^a,b   Riley, Julia ^a,b,c   Ross, Joy ^a,b,c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Analgesia; Opioid; Opioid response; Opioid switching; Pharmacogenetics

Indexed keywords

NARCOTIC ANALGESIC AGENT;

EPISTAXIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; NEOPLASM; PAIN; PHARMACOGENETICS; PHENOTYPE; REVIEW;

ANALGESICS, OPIOID; EPISTAXIS; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEOPLASMS; PAIN; PHARMACOGENETICS; PHENOTYPE;

EID: 84861805876     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32834f6a07     Document Type: Review

References (52)

1. King SJ, Reid C, Forbes K, Hanks G. A systematic review of oxycodone in the management of cancer pain. Palliat Med 2011; 25:454-470.
2. Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. Palliat Med 2011; 25:471-477.
3. Tassinari D, Drudi F, Rosati M, Maltoni M. Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review. Palliat Med 2011; 25:478-487.
4. Cherny N. Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain? Palliat Med 2011; 25:488-493.
5. Bekkering GE, Soares-Weiser K, Reid K, et al. Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses. Curr Med Res Opin 2011; 27:1477-1491.
6. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med 2011; 25:402-409.
7. Gosso MF, Barrett CF, van den Maagdenberg A, Ferrari MD. Pain-related mutations in the human genome. In: Mogil JS, editor. Pain 2010 - an updated review. Seattle: IASP Press; 2010.
8. Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006; 444:894-898.
9. Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006; 52:767-774.
10. Scherrer G, Imamachi N, Cao YQ, et al. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 2009; 137:1148-1159.
11. Pasternak GW. Molecular insights into mu opioid pharmacology: from the clinic to the bench. Clin J Pain 2010; 26 (Suppl. 10):S3-S9.
12. Kim H, Clark D, Dionne RA. Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J Pain 2009; 10:663-693.
13. Williams FM, Spector TD, MacGregor AJ. Pain reporting at different body sites is explained by a single underlying genetic factor. Rheumatology (Oxford) 2010; 49:1753-1755.
14. Livshits G, Popham M, Malkin I, et al. Lumbar disc degeneration and genetic factors are the main risk factors for low back pain in women: the UK Twin Spine Study. Ann Rheum Dis 2011; 70:1740-1745.
15. Hartvigsen J, Nielsen J, Kyvik KO, et al. Heritability of spinal pain and consequences of spinal pain: a comprehensive genetic epidemiologic analysis using a population-based sample of 15,328 twins ages 20-71 years. Arthritis Rheum 2009; 61:1343-1351.
16. Norbury TA, MacGregor AJ, Urwin J, et al. Heritability of responses to painful stimuli in women: a classical twin study. Brain 2007; 130 (Pt 11):3041-3049.
17. Nielsen CS, Stubhaug A, Price DD, et al. Individual differences in pain sensitivity: genetic and environmental contributions. Pain 2008; 136:21-29.
18. Angst MS, Phillips NG, Drover DR, et al. Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability. Twin Res Hum Genet 2010; 13:412-425.
19. Wild D. Twin study points to genetic factors in opioid response. Pain Medicine News; 2010.
20. Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009; 146:270-275.
21. Lotsch J, von Hentig N, Freynhagen R, et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 2009; 19:429-436.
22. Mogil JS. Are we getting anywhere in human pain genetics? Pain 2009; 146:231-232.
23. Shabalina SA, Zaykin DV, Gris P, et al. Expansion of the human {micro}-opioid receptor gene architecture: novel functional variants. Hum Mol Genet 2008; 18:1037-1051.
24. Lotsch J, Klepstad P, Doehring A, Dale O. A GTP cyclohydrolase 1 genetic variant delays cancer pain. Pain 2011; 148:103-106.
25. Doehring A, Freynhagen R, Griessinger N, et al. Cross-sectional assessment of the consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain care. Clin J Pain 2009; 25:781-785.
26. Droney J, Riley J, Ross JR. Evolving knowledge of opioid genetics in cancer pain. Clin Oncol (R Coll Radiol) 2011; 23:418-428.
27. Lotsch J, Geisslinger G. A critical appraisal of human genotyping for pain therapy. Trends Pharmacol Sci 2010; 31:312-317.
28. Laugsand EA, Fladvad T, Skorpen F, et al. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur J Cancer 2011; 47:1682-1691.
29. Andreassen TN, Eftedal I, Klepstad P, et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol 2011 [Epub ahead of print].
30. Galvan A, Skorpen F, Klepstad P, et al. Multiple loci modulate opioid therapy response for cancer pain. Clin Cancer Res 2011; 17:4581-4587.
31. Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011; 152:1139-1145.
32. Kim H, Ramsay E, Lee H, et al. Genome-wide association study of acute postsurgical pain in humans. Pharmacogenomics 2009; 10:171-179.
33. Smith SB, Tchivileva IE, Maixner W, Diatchenko L. The search for human pain genetics using whole-genome approaches: achievements, failures and promises. In: Mogil JS, editor. Pain 2010 - an updated review. Seattle: IASP Press; 2010.
34. Diatchenko L, Nackley AG, Tchivileva IE, et al. Genetic architecture of human pain perception. Trends Genet 2007; 23:605-613.
35. Kolesnikov Y, Gabovits B, Levin A, et al. Combined catechol-O- methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth Analg 2011; 112:448-453.
36. Campa D, Gioia A, Tomei A, et al. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83:559-566.
37. Ross JR, Riley J, Taegetmeyer AB, et al. Genetic variation and response to morphine in cancer patients: catechol-o-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 2008; 112:1390-1403.
38. Hu T, Sinnott-Armstrong NA, Kiralis JW, et al. Characterizing genetic interactions in human disease association studies using statistical epistasis networks. BMC Bioinformatics 2011; 12:364-376.
39. Cowper-Sall R, Cole MD, Karagas MR, et al. Layers of epistasis: genomewide regulatory networks and network approaches to genome-wide association studies. Wiley Interdiscip Rev Syst Biol Med 2011; 3:513-526.
40. Novembre J, Johnson T, Bryc K, et al. Genes mirror geography within Europe. Nature 2008; 456:98-101.
41. Chanock SJ, Manolio T, Boehnke M, et al. Replicating genotype-phenotype associations. Nature 2007; 447:655-660.
42. Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage 2011; 41:1073-1093.
43. Lotsch J, RohrbacherM, Schmidt H, et al. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 2009; 144:119-124.
44. Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology 2011; 87:274-285.
45. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet agerelated macular degeneration. Science 2006; 314:989-992.
46. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-1388.
47. Binder A, May D, Baron R, et al. Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS One 2011; 6:e17387.
48. Tsao D, Shabalina SA, Gauthier J, et al. Disruptive mRNA folding increases translational efficiency of catechol-O-methyltransferase variant. Nucleic Acids Res 2011; 39:6201-6212.
49. Reimann F, Cox JJ, Belfer I, et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci USA 2010; 107:5148-5153.
50. Olgiati P, Bajo E, Bigelli M, et al. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36:147-154.
51. Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med 2011; 25:494-503.
52. Mercadante S, Ferrera P, Villari P, et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009; 37:632-641.